I very familiar with the MS field. Quarter in and quarter Dew posts on this board the sales results of copaxone versus the rest of the drugs, and sales are impressive.
What we don't realize is 'why' Teva's sales are so good. It's not the drug's performance nor their pricing (which doubled over the last 5 years), but more it's because of Teva's relationship with the neurological field.